<DOC>
	<DOCNO>NCT00764374</DOCNO>
	<brief_summary>To examine safety efficacy Z-338 ( YM443 ) long-term administration patient functional dyspepsia , also examine pattern long-term administration .</brief_summary>
	<brief_title>A Long-term , Open-label , Uncontrolled Trial YM443 ( Z-338 ) Patients With Functional Dyspepsia</brief_title>
	<detailed_description />
	<mesh_term>Dyspepsia</mesh_term>
	<mesh_term>Gastritis</mesh_term>
	<criteria>Patient show least one follow 4 symptom 6 month obtain consent postprandial fullness early satiation upper abdominal pain upper abdominal discomfort Patient show least 2 8 symptom show repeatedly 3 month obtain consent ( At least one symptom either postprandial fullness early satiation include . ) Patient show either postprandial fullness , bloat upper abdomen , early satiation major complaint among 8 symptom show time obtain consent upper abdominal pain upper abdominal discomfort postprandial fullness bloat upper abdomen early satiation nausea vomit belch Outpatient Patient show symptom organic disease ( reflux esophagitis , erosion , ulceration , esophageal hiatal hernia , bleeding , malignant tumor , Barrett 's esophagus ) upper gastrointestinal endoscopy perform within 24 week obtain consent Patient show heartburn within 12 week obtain consent Patient complicate irritable bowel syndrome Patient complicate diabetes mellitus require medication Patient complicate severe anxiety disorder problem interpersonal relationship social life Patient complicate depression ( include suspect case ) sleep disturbance</criteria>
	<gender>All</gender>
	<minimum_age>20 Years</minimum_age>
	<maximum_age>79 Years</maximum_age>
	<verification_date>October 2014</verification_date>
	<keyword>YM443</keyword>
	<keyword>Z-338</keyword>
	<keyword>Acotiamide</keyword>
	<keyword>Rome III</keyword>
	<keyword>Signs symptom , digestive</keyword>
</DOC>